Genes determine trastuzumab response in breast cancer trial
Added: Monday 2 February 2015
Research into the effects of trastuzumab (also known as herceptin) finds that genes relating to patient immune function were key to determining response to the drug. The research was done on patients with human epidermal growth factor receptor 2 (HER2) positive breast cancer. Those with high levels of immune genes had greater relapse-free survival on trastuzumab than those without.
In order to be able to see the content from the www.medscape.com pages, please create first a free account at following link: